ClinicalTrials.gg
Active, not recruitingNCT06458049Updated Feb 24, 2026

Sexual Health and Rehabilitation Online (SHAREonline)

An interventional study of Group Session and Coaching Call in Cancer Survivorship and Sexual Function Disturbances, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 1 site in United States. Open to female participants aged 19 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
19 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.

Enrollment
36th of 59
84 · median 196
Started
2025
with 1 other
No phase
14 of 62
1 open now
Registered
61st of 62
by date
Lead sponsor
2 of 62
Dana-Farber Cancer Institute

Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is the 36th largest by enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 61st registered.

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

Browse Sexual Dysfunctions, Psychological studies →

Open to participants now

3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 19 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Sexual Dysfunctions, Psychological with a site in United States, or all of them as a file.
02

Study summary

SHAREonline is a study for young female cancer survivors that are experiencing changes in sexual health and function.

The purpose of this research is to compare two brief interventions delivered by videoconference to learn if they help women effectively manage these changes and restore sexual health and functioning.

Read the detailed description

The purpose of this research is to compare two brief interventions delivered by videoconference to learn if they help women effectively manage these changes and restore sexual health and functioning.

Participants in this study would first complete health questionnaires and then be randomized to take part in one of two types of education sessions delivered by an instructor over videoconference: 1) Group education session or 2) Individual self-management session.

About 56 women will receive the group education session and about 28 will receive the individual self-management session.

It is expected that about 84 women will take part in this study.

03

Conditions studied

  • Cancer Survivorship
  • Sexual Function Disturbances

Keywords

  • Cancer Survivorship
  • Sexual Function Disturbances
04

Who can participate

Ages eligible
19 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

  • Female cancer survivors age 19-49
  • Cancer diagnosis (except non-melanoma skin cancer) ≥ 1 year prior
  • Diagnosed with first cancer ≥ age 18
  • No active cancer therapy (excluding chemoprevention) in the past four months, and no further therapy planned
  • Ability to read and write in English
  • Bothered by significant sexual dysfunction as evidenced by a Female Sexual Functioning Index (FSFI) score of ≤26.
  • Regular access to the internet

Exclusion Criteria

  • Has never been sexually active
  • Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all study procedures independently
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    SHAREonline

    Participants will receive: * One online group session structured around three 60-minute modules and creation of a personal action plan * Single Coaching phone call at one month * Questionnaires to complete at baseline, 2 and 4 Months

    Behavioral: Group Session · Behavioral: Coaching Call

  • Active comparator
    Individual Self Management

    Brief individualized session with online and written materials and guidance. All Participants will complete study questionnaires at baseline, 2 months and 4 months post intervention

    Behavioral: Educational Materials

Interventions

  • BehavioralGroup Session

    On-line educational session-3 modules-1 hour each for a total of 3 hours

  • BehavioralCoaching Call

    Single Coaching phone call at one month

  • BehavioralEducational Materials

    Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer

06

What researchers measure

Primary outcomes

  1. Change in Sexual Function

    The Female Sexual Function Index (FSFI Full Scale Score), is 19-item instrument which measures sexual function, including desire, orgasm, pain and satisfaction.

    Time frame: Baseline to 2 months

Secondary outcomes

  1. Change in Emotional Distress

    BSI-18 (Brief Symptom Inventory) The BSI-18 is a well-validated screening measure of psychological distress with subscales measuring anxiety, depression and somatization that is frequently used with oncology populations.

    Time frame: Baseline to 2 month

  2. Change in Sexual Function

    The Female Sexual Function Index (FSFI Full Scale Score), is 19-item instrument which measures sexual function, including desire, orgasm, pain and satisfaction.

    Time frame: Baseline to 4 months

  3. Change in Emotional Distress

    BSI-18 (Brief Symptom Inventory) The BSI-18 is a well-validated screening measure of psychological distress with subscales measuring anxiety, depression and somatization that is frequently used with oncology populations.

    Time frame: Baseline to 4 months

  4. Enrollment Rate

    Measured through study accrual with a benchmark of enrollment greater than or equal to 40% of eligible candidates

    Time frame: Baseline to 1 month

  5. Intervention Acceptability Rate

    Intervention Satisfaction Questionnaire will be assessed using a benchmark mean score of 4

    Time frame: Up to 1 month-post intervention

  6. Study Engagement Rate

    Measured through study engagement with a benchmark of study engagement greater than or equal to 70% of eligible candidates

    Time frame: Baseline to 1 month

  7. Intervention Completion Rate

    Measured through intervention completion with a benchmark of intervention completion greater than or equal to 60% of eligible candidates

    Time frame: Baseline to 4 months

  8. Distress about Sexual Function

    Sexual Distress Scale-short form (SDS-SF) is a 5-item measure which assesses distress about sexual function.

    Time frame: Baseline to 2 months

  9. Distress about Sexual Function

    Sexual Distress Scale-short form (SDS-SF) is a 5-item measure which assesses distress about sexual function.

    Time frame: Baseline to 4 months

  10. Sexual Function, Satisfaction and Sexual Inactivity

    PROMIS Sexual Function and Satisfaction (PROMIS SexFS) is a short screening

    Time frame: Baseline to 2 months

Other outcomes

  1. Sexual Self-efficacy

    Sexual Self-Efficacy Scale is a 5-item scale developed to measure perceived sexual self-efficacy to address sexual health after cancer.

    Time frame: Baseline to 2 months

  2. Sexual Self-efficacy

    Sexual Self-Efficacy Scale is a 5-item scale developed to measure perceived sexual self-efficacy to address sexual health after cancer.

    Time frame: Baseline to 4 months

  3. Coaching Satisfaction Summary

    Brief participant questionnaire to provide feedback about coaching session.

    Time frame: Up to 1 month post-coaching session

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.

Of 30 non-industry interventional studies with no phase under Sexual Dysfunctions, Psychological, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 27 months is above that.

Counting every sponsor, half of 30 studies reached it within 21 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 13, 2024
StartActual
Feb 19, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06458049
Responsible party
Sharon Bober, Ph.D (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Jun 13, 2024
Start date
Feb 19, 2025
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Feb 24, 2026

Study contacts

Sharon Bober, PhD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion